ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2295

Mortality In Early Rheumatoid Arthritis Comparing Lithuania and Finland. A 13-Year Follow Up

Tuulikki Sokka1, Sigita Stropuviene2, Hannu Kautiainen3, Tuomas Rannio4 and Jolanta Dadoniene2, 1Rheumatology, Jyvaskyla Central Hospital, Jyvaskyla, Finland, 2Vilnius Univ, Vilnius, Lithuania, 3Unit of Primary Health Care, Helsinki University Central Hospital, Helsinki, Finland, 4Jyvaskyla Central Hospital, Jyväskylä, Finland

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Title: Rheumatoid Arthritis-Clinical Aspects III: Outcome Measures, Socioeconomy, Screening, Biomarkers in Rheumatoid Arthritis

Session Type: Abstract Submissions (ACR)

Background/Purpose: Life span of patients with rheumatoid arthritis (RA) is reduced by 3-10 years compared to non-RA population. Only recent reports indicate improvements in survival outcomes in RA in a few countries. The QUEST-RA study indicated that RA continues to be an active and severe disease especially in countries with lower gross domestic product (ARD 2009;68:1666-7). Therefore, it is of interest to compare survival outcomes of patient with RA in different countries. Our objective was to study long-term survival of patients with early RA in Vilnius (VIL), Lithuania, and Jyväskylä (JYV), Finland, and predictors of vital status as well as comparison to the population.

Methods: A cohort of 191 patients with early RA (disease duration <4 years) was established in VIL in 1998 – 2003. A comparison cohort was drawn from the JYV RA database that includes all incident and prevalent patients with RA since 1982. To each VIL patient, a control subject was identified in JYV, matched for gender, year of birth, starting year of arthritis, and RF status (negative, positive). Vital status of the patients was acquired from the central statistics office in each country. Regression analyses for mortality included nation, baseline disease activity(DAS28_esr3), patient self-report of function(HAQ), early continuous use of DMARDs and systemic steroids(SS), presence of a life threatening disease(LTD), smoking, and a type of work (white vs blue collar) as a proxy of wealth. Patients were followed until December 2012 or death, which ever happened first. Standard Mortality Ratio (SMR) was calculated.

Results: A total of 186 patients and controls (age at diagnosis 52 years, 78%F, 85% RF+) were included in analyses. Over a median (IQR) follow-up of 13 (11, 15) years, 55 and 32 patients died in VIL and JYV, respectively, including 16(40%) and 11(28%) of men (p=0.24) and 39(27%) and 21(15%) of women (p=0.009) [HR=1.83 (95% CI: 1.18 to 2.83), p<0.001] . In multivariate analysis, age and country were the only independently significant variables for mortality. SMR (95%CI) was similar to that of the population in each country (VIL: 1.3, 1.0 to 1.7; JYV: 1.4, 1.0 to 1.9).

Conclusion: In this analysis of patients with early RA over a median of 13 years, higher mortality was seen in VIL compared to JYV patients but SMR was similar to the general population in each country indicating improved outcomes of RA in these countries.


Disclosure:

T. Sokka,
None;

S. Stropuviene,
None;

H. Kautiainen,
None;

T. Rannio,
None;

J. Dadoniene,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/mortality-in-early-rheumatoid-arthritis-comparing-lithuania-and-finland-a-13-year-follow-up/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology